Suzhou Zelgen BiopharmaceuticalsLtd Past Earnings Performance
Past criteria checks 0/6
Suzhou Zelgen BiopharmaceuticalsLtd has been growing earnings at an average annual rate of 10.3%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been growing at an average rate of 52.4% per year.
Key information
10.3%
Earnings growth rate
17.3%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 52.4% |
| Return on equity | -14.6% |
| Net Margin | -35.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Earnings Haven't Escaped The Attention Of Investors
Nov 27
Some Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266) Analysts Just Made A Major Cut To Next Year's Estimates
Sep 11What Does The Future Hold For Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHSE:688266)? These Analysts Have Been Cutting Their Estimates
May 08Suzhou Zelgen Biopharmaceuticals Co.,Ltd.'s (SHSE:688266) Shares Climb 28% But Its Business Is Yet to Catch Up
Mar 06Revenue & Expenses Breakdown
How Suzhou Zelgen BiopharmaceuticalsLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 488 | -174 | 304 | 434 |
| 30 Jun 24 | 407 | -231 | 289 | 457 |
| 31 Mar 24 | 387 | -261 | 263 | 489 |
| 31 Dec 23 | 386 | -279 | 265 | 496 |
| 30 Sep 23 | 387 | -296 | 289 | 440 |
| 30 Jun 23 | 417 | -325 | 308 | 463 |
| 31 Mar 23 | 367 | -395 | 334 | 468 |
| 31 Dec 22 | 302 | -457 | 314 | 498 |
| 30 Sep 22 | 290 | -522 | 295 | 565 |
| 30 Jun 22 | 253 | -521 | 279 | 567 |
| 31 Mar 22 | 234 | -491 | 254 | 547 |
| 31 Dec 21 | 190 | -451 | 220 | 509 |
| 30 Sep 21 | 98 | -384 | 177 | 429 |
| 30 Jun 21 | 70 | -368 | 126 | 382 |
| 31 Mar 21 | 28 | -337 | 98 | 338 |
| 31 Dec 20 | 28 | -319 | 93 | 314 |
| 30 Sep 20 | 28 | -292 | 76 | 284 |
| 30 Jun 20 | 0 | -249 | 70 | 237 |
| 31 Mar 20 | 0 | -354 | 145 | 208 |
| 31 Dec 19 | 0 | -462 | 266 | 184 |
| 30 Sep 19 | 0 | -747 | 564 | 171 |
| 31 Dec 18 | 1 | -440 | 319 | 143 |
| 31 Dec 17 | 0 | -146 | 7 | 159 |
| 31 Dec 16 | 0 | -128 | 74 | 61 |
Quality Earnings: 688266 is currently unprofitable.
Growing Profit Margin: 688266 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688266 is unprofitable, but has reduced losses over the past 5 years at a rate of 10.3% per year.
Accelerating Growth: Unable to compare 688266's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 688266 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (1.3%).
Return on Equity
High ROE: 688266 has a negative Return on Equity (-14.62%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 09:56 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ziyu He | China International Capital Corporation Limited |
| Shitong Han | Citic Securities Co., Ltd. |
| Yinhao Tang | Citic Securities Co., Ltd. |